Bionano Genomics Inc. (BNGO) shares tumble 417.62% on Wednesday: A Good Option for Optimistic Investors

Bionano Genomics Inc. (BNGO) is owned by a number of high-value investors. Its largest direct holder is Mark Borodkin Chief Operating Officer with 6,815 shares. The second-largest direct holder is David L. Barker Chairman of the Board, with 3,894 shares of the company’s stock.

Now turning to institutional ownership of Bionano Genomics Inc. (BNGO), Sio Capital Management LLC is the top holder with 1.52 million shares. The next largest fund holder of this company’s stock is AIGH Capital Management LLC with 651802 shares. In the third-place spot with 87513 shares is Worth Venture Partners LLC.

This company’s stock price was $2.85 at the previous market close, with its latest volume reaching 34390202. Compare that to its average daily volume of 99.09K. Given the fact that this stock has 10.62M shares outstanding, its current market value is sitting at $30.27M. Its Price to Sales ratio is 2.78, its Price to Cash Flow ratio is 1.98.

BNGO stock has achieved a 5-day range of $0.50 to $4.70, with a total performance of +391.38% during that period. Meanwhile, in the past month of trading, this stock has traded in the range of $0.50 to $4.70, generating a +141.53% change during the period. In the past three months, this stock’s price has changed by +12.65%, trading in the range of $0.50 to $4.70.

In the past 5 days, shares of BNGO have made a new high 4 times. In the last month, it has made a new high 2 times, and in the past 3 months, it has made a new high 7 times.

Now let’s turn to this public company’s earnings. For the quarter ending 6/29/2019, the earnings per share (EPS) was reported at -0.71. This is a -0.12 difference compared to the consensus estimate of -0.59, amounting to an earnings surprise of -20.30%. In the previous quarter, which ended in 6/29/2019, the consensus estimate was -0.56, making for an earnings surprise of -37.50%. For the quarter ending 12/30/2018, EPS was reported at -0.62, generating a -34.80% earnings surprise.

The Net Income for the most recent full fiscal year, which ended in 12-2018, was $-18.5 million. This is compared to the prior year, where Net Income was $-23.36 million. Capital Expenditures for the year were reportedly $332000, compared to -$1.02 million, and Free Cash flow was $-20.28 million compared to the prior year’s $-21.84 million.

Bionano Genomics Inc. (BNGO) stock currently has a Financial Strength score of 2.2/10. This is due to a combination of factors, including a Cash to Debt ratio of 0.79, an Equity to Asset ratio of -0.05, a Debt to Equity ratio of -14.44 and a Debt to EBITDA of -0.8. The Altman Z-Score is -6.74.

This publicly-traded company’s Profitability and Growth score is 1/10, thanks to a combination of things: an Operating Margin of -230.86, a Net Margin of -247.02 and a ROC of -708.42.

Shifting focus now to Valuation and Return for BNGO, this company’s Price to Median PS Value is 0.81. Price to Peter Lynch Fair Value for BNGO is now 0.00.

Certain ratios provide helpful insights into how a stock is performing. The Quick Ratio for BNGO is sitting at 2.77, while its Current Ratio is 3.17. This stock’s PS Ratio is 2.07.